HRWR: Predicting Potential Efficacious Drug Combination Based on Hypergraph Random Walk with Restart

Author:

Wang QiORCID,Yan Guiying

Abstract

AbstractSome studies have shown that efficacious drug combination can increase the therapeutic effect, and decrease drug toxicity and side-effects. Thus, drug combinations have been widely used in the treatment of complex diseases, especially cancer. However, experiment-based methods are extremely costly in time and money. Computational models can greatly reduce the cost, but most of the models do not use the data of more than two drugs and lose a lot of useful information. Here, we used high-order drug combination information and developed a hypergraph random walk with restart model (HRWR) for efficacious drug combination prediction.As a result, compared with the other methods by leave-one-out cross-validation (LOOCV), the Area Under Receiver Operating Characteristic Curve (AUROC) of the HRWR algorithm were higher than others. Moreover, the case studies of lung cancer, breast cancer, and colorectal cancer showed that HRWR had a powerful ability to predict potential efficacious combinations, which provides new prospects for cancer treatment. The code and dataset of HRWR are freely available at https://github.com/wangqi27/HRWR.

Publisher

Cold Spring Harbor Laboratory

Reference51 articles.

1. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

2. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

3. Backstrom, L. , and Leskovec, J. (2011). “Supervised random walks,” in Proceedings of the fourth ACM international conference on Web search and data mining - WSDM ‘11, eds. I. King , W. Nejdl , and H. Li (New York, New York, USA: ACM Press), 635.

4. Calcium and vitamin D: Promising or proven;Cancer Research,2008

5. Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3